Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Myriad™ Augmented Soft Tissue Reconstruction Registry

NCT05243966 · View on ClinicalTrials.gov ↗

Study Summary

This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll participants who are undergoing a surgical procedure, where the attending physician will use Myriad™ as part of the surgical intervention.

Interventions

  • DEVICE Myriad Matrix™ and Myriad Morcells™

Study Locations (13)

Florida

  • Associates in Medicine & Surgery — Fort Myers
  • Asencion Sacred Heart — Pensacola

Louisiana

  • University Medical Center — New Orleans
  • Ochsner Baptist Medical Center — New Orleans

Pennsylvania

  • Lancaster General Hospital — Lancaster
  • Tower Health Reading Hospital — West Reading

California

  • Surgery Group LA — Los Angeles

Georgia

  • Northeast Georgia Medical Center, Inc. — Gainesville

Maryland

  • Sinai Hospital of Baltimore — Baltimore

New York

  • Nuvance Health Vassar Brothers Medical Center — Poughkeepsie

North Carolina

  • Moses H Cone Memorial Hospital Operating Corporation — Greensboro

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2022-01-10
Est. Completion 2029-01

Sponsor

Aroa Biosurgery Limited

3 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05243966

The ClinicalTrials.gov registry entry for NCT05243966 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aroa Biosurgery Limited, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 7 conditions, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention — of which Myriad Matrix™ and Myriad Morcells™ is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05243966 reports 13 study locations spanning 10 distinct geographic areas — top geographies include Florida, Louisiana, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05243966 about?

NCT05243966 is a clinical study titled "Myriad™ Augmented Soft Tissue Reconstruction Registry". This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll participants who are undergoing a surgical procedure, where the attending physician will use Myriad™ as part of the surgical intervention.

What is the current status of trial NCT05243966?

This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2022-01-10. Estimated completion is 2029-01.

What conditions does trial NCT05243966 study?

This clinical trial studies the following conditions: Hidradenitis Suppurativa, Pressure Injury, Anal Fistula, Necrotizing Soft Tissue Infection, Lower Extremity Wound. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05243966?

The interventions under investigation include: Myriad Matrix™ and Myriad Morcells™ (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05243966?

This trial is sponsored by Aroa Biosurgery Limited, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05243966 being conducted?

This trial has 13 study locations across California, Florida, Georgia, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial